@prefix np: . @prefix npx: . @prefix ns1: . @prefix ns2: . @prefix ns3: . @prefix orcid: . @prefix prov: . @prefix rdf: . @prefix rdfs: . @prefix sub: . @prefix this: . @prefix xsd: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { ns3:consider . } sub:provenance { sub:_assertion prov:wasGeneratedBy "S&T TWOC Project - version 4", "S&T TWOC version 3" . sub:_version prov:value "2"^^xsd:integer . sub:assertion prov:generatedAtTime "2023-07-20T09:47:13.868775"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0003-4692-1377; prov:wasDerivedFrom . rdf:OBJECT rdfs:label "for COVID-19 therapy" . rdf:OBJECT-POSITION rdfs:label "(226, 238)" . rdf:PREDICATE rdfs:label "considered" . rdf:PREDICATE-POSITION rdfs:label "498" . rdf:SUBJECT rdfs:label "other antibiotics like azithromycin , ivermectin , eravacycline , valrubicin , streptomycin , nitazoxanide , teicoplanin , caspofungin , and colistin ; and other agents like hydroxychloroquine , chloroquine , tocilizumab , camostat , nafamostat , carfilzomib , interferon , aprepitant , and dexamethasone" . rdf:SUBJECT-POSITION rdfs:label "(226, 238)" . rdf:Statement rdfs:label "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . rdfs:ABSTRACT-UID ns2:50 "8j41d0a3" . rdfs:TRIPLE-UID ns1:8j41d0a3-TRIPLE-ABSTRACT-2 "8j41d0a3-TRIPLE-ABSTRACT-2" . rdfs:label "azithromycin" . rdfs:label "therapy" . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "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"; npx:hasSignature "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"; npx:hasSignatureTarget this: . this: prov:wasAttributedTo orcid:0000-0003-4692-1377 . }